CN103874490A - 咔咯和他汀类药物的组合 - Google Patents

咔咯和他汀类药物的组合 Download PDF

Info

Publication number
CN103874490A
CN103874490A CN201280050749.6A CN201280050749A CN103874490A CN 103874490 A CN103874490 A CN 103874490A CN 201280050749 A CN201280050749 A CN 201280050749A CN 103874490 A CN103874490 A CN 103874490A
Authority
CN
China
Prior art keywords
statins
transition metal
rising
click
metal complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280050749.6A
Other languages
English (en)
Chinese (zh)
Inventor
泽埃夫·格罗斯
迈克尔·阿维拉姆
阿迪·哈伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technion Research and Development Foundation Ltd
Original Assignee
Technion Research and Development Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research and Development Foundation Ltd filed Critical Technion Research and Development Foundation Ltd
Publication of CN103874490A publication Critical patent/CN103874490A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280050749.6A 2011-08-15 2012-08-14 咔咯和他汀类药物的组合 Pending CN103874490A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161523476P 2011-08-15 2011-08-15
US61/523,476 2011-08-15
PCT/IB2012/054124 WO2013024425A1 (en) 2011-08-15 2012-08-14 Combinations of corroles and statins

Publications (1)

Publication Number Publication Date
CN103874490A true CN103874490A (zh) 2014-06-18

Family

ID=47003157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280050749.6A Pending CN103874490A (zh) 2011-08-15 2012-08-14 咔咯和他汀类药物的组合

Country Status (9)

Country Link
US (1) US9642860B2 (enExample)
EP (1) EP2744492A1 (enExample)
JP (1) JP2014521738A (enExample)
CN (1) CN103874490A (enExample)
BR (1) BR112014003529A2 (enExample)
CA (1) CA2845301A1 (enExample)
IL (1) IL230988A0 (enExample)
MX (1) MX2014001823A (enExample)
WO (1) WO2013024425A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105440043A (zh) * 2015-08-06 2016-03-30 南京林业大学 一种冰片酯基咔咯衍生物及其制备方法
CN108752354A (zh) * 2018-06-11 2018-11-06 三峡大学 一种卟啉荧光染料的合成及其方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637731B2 (en) * 2013-03-05 2017-05-02 Innovative Environmental Technologies, Inc. Heavy metal stabilization and methane inhibition during induced or naturally occurring reducing conditions in contaminated media
US9221699B2 (en) * 2013-03-05 2015-12-29 Innovative Environment Technologies, Inc. Inhibition of methane production during anaerobic reductive dechlorination
EP3730155A1 (en) * 2013-05-08 2020-10-28 Cedars-Sinai Medical Center Targeting corroles for tumor toxicity and mri

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043721A1 (en) * 2000-11-29 2002-06-06 Centre For Molecular Biology And Medicine Treatment of statin side effects
WO2009027965A1 (en) * 2007-08-28 2009-03-05 Technion Research And Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126426A0 (en) 1998-09-29 1999-05-09 Technion Res & Dev Foundation Process for the preparation of corroles several such new compounds including chiral derivatives and the use thereof
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
ATE472550T1 (de) 2001-07-02 2010-07-15 Technion Res & Dev Foundation Verfahren zur herstellung selektiv substituierter corrole und neue substituierte corrole
KR100742432B1 (ko) 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
KR100918325B1 (ko) 2007-06-05 2009-09-22 충남대학교산학협력단 고콜레스테롤 치료용 복합제제 및 이의 제조방법
US20110098262A1 (en) 2008-01-31 2011-04-28 Yondim Moussa B H Corroles for neuroprotection and neurorescue
MX344885B (es) 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
US8680266B2 (en) 2009-05-22 2014-03-25 California Institute Of Technology Metallocorroles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043721A1 (en) * 2000-11-29 2002-06-06 Centre For Molecular Biology And Medicine Treatment of statin side effects
WO2009027965A1 (en) * 2007-08-28 2009-03-05 Technion Research And Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘学辉: "他汀类药物的临床应用进展", 《当代医学》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105440043A (zh) * 2015-08-06 2016-03-30 南京林业大学 一种冰片酯基咔咯衍生物及其制备方法
CN108752354A (zh) * 2018-06-11 2018-11-06 三峡大学 一种卟啉荧光染料的合成及其方法

Also Published As

Publication number Publication date
WO2013024425A1 (en) 2013-02-21
IL230988A0 (en) 2014-03-31
EP2744492A1 (en) 2014-06-25
MX2014001823A (es) 2014-08-21
US9642860B2 (en) 2017-05-09
US20140200204A1 (en) 2014-07-17
CA2845301A1 (en) 2013-02-21
JP2014521738A (ja) 2014-08-28
BR112014003529A2 (pt) 2017-03-14

Similar Documents

Publication Publication Date Title
US20240148681A1 (en) Fixed dose combinations and formulations comprising etc1002 and one or more statins and methods of treating or reducing the risk of cardiovascular disease
US12115137B2 (en) Synergistic combinations of atorvastatin and cannabidiol (CBD)
KR20020019450A (ko) 암로디핀 및 아토르바스타틴의 상호 염
CN103874490A (zh) 咔咯和他汀类药物的组合
EP1089731A1 (en) Compositions and methods for treating elevated blood cholesterol
AU2015237273B2 (en) Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
AU726822B2 (en) Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
Bays Extended-release niacin/lovastatin: the first combination product for dyslipidemia
KR20240040767A (ko) His 저감반응자의 치료
KR101258422B1 (ko) 신규의 트리글리세리드 저하제
JPWO2001085155A1 (ja) 動脈硬化抑制方法及び組成物
JP2007513991A (ja) メタボリック症候群の処置のためのスタチンの使用
WO2001085155A1 (en) Method and compositions for inhibiting arteriosclerosis
KR100725263B1 (ko) ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제
US20050182036A1 (en) Medicinal composition containing an HMG-CoA reductase inhibitor
WO2004096276A9 (ja) 糖取り込み能増強剤
Petyaev et al. Reduction of cholesterol and markers of oxidation in serum of hypercholesterolemic patients treated with lycosome formulation of simvastatin
JP2007528369A5 (enExample)
Goldberg et al. 1084-174 Efficacy of ezetimibe-10 mg/day coadministered with multiple doses of simvastatin in patients with primary hypercholesterolemia
HK40107190A (en) Fixed dose combinations and formulations comprising etc1002 and one or more statins and methods of treating or reducing the risk of cardiovascular disease
CA2494801A1 (en) Medicinal composition containing hmg-coa reductase inhibitor
EA009918B1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ВЫСШИЕ ПЕРВИЧНЫЕ АЛИФАТИЧЕСКИЕ СПИРТЫ И ИНГИБИТОР ГМГ-КоА-РЕДУКТАЗЫ, И СПОСОБ ИХ ПОЛУЧЕНИЯ
WO2018017726A1 (en) Methods and compositions for alleviating myopathy
JP2007308484A (ja) 高脂血症の予防及び／又は治療のための医薬
JP2013032400A (ja) ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物２

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140618